摘要
簇集蛋白(CLU)是一种广泛存在于哺乳动物各种体液中并在各种组织中表达的糖蛋白。CLU参与多种生理病理过程。在多种恶性肿瘤中均发现有CLU表达的改变。在乳腺癌的研究中,CLU被认为与乳腺癌的发生和发展相关,CLU高表达可能是乳腺癌不良预后指标之一。CLU参与乳腺癌综合治疗耐药机制的产生,抗CLU治疗可以增加乳腺癌对化学治疗、内分泌治疗和靶向治疗的敏感性,然而其临床有效性尚未达到Ⅱ期临床试验的标准。
Clusterin（CLU） is an enigmatic glycoprotein with a nearly ubiquitous tissue distribution,apparently involved in many biological processes and pathological states.Its expression has been demonstrated to have changed in many malignancies.In breast cancer,CLU was reported to correlate with the tumorigenesis and progression of the malignancy,and high expression of CLU may be a poor prognosis of breast cancer in survival analysis.The cytoprotective function of CLU in breast carcinoma cells was demonstrated to be involved in the resistance mechanism of conventional chemotherapy,endocrine therapy and targeted therapy of breast cancer and it has been investigated on the capacity of anti-CLU treatment to sensitize breast carcinoma cells to multiple therapy strategies,however,there were insufficient responses to meet the criteria for proceeding to the second stage of accrual in clinical trials.
出处
《医学综述》
2011年第9期1328-1331,共4页
Medical Recapitulate
关键词
簇集蛋白
乳腺癌
化学治疗
内分泌治疗
靶向治疗
Clusterin
Breast cancer
Chemotherapy
Endocrine therapy
Targeted therapy
